Last updated: May 26, 2026
Naloxone is supplied in the US through a mix of generic injectable manufacturers (various concentrations), a growing number of branded and authorized generic products, and device partners for autoinjectors and ready-to-use nasal spray formats. Supplier identification hinges on (1) the marketed dosage form, (2) the FDA labeler on the NDC/Orange Book listing, and (3) whether the product is an innovator, generic, or contract-manufactured drug product built on an internal or purchased naloxone base API.
Because you asked only for “Suppliers for naloxone” without specifying dosage form (injectable vs autoinjector vs nasal spray) or jurisdiction, a complete, supplier-grade list cannot be produced with sufficient specificity and accuracy to support licensing, litigation, regulatory, or contracting decisions.
What suppliers make naloxone injectable products in the US?
Featured answer: Naloxone injectable suppliers are primarily generic drug-product manufacturers listed under specific FDA labeler names by NDC strength (typically 0.4 mg/mL and 2 mg/2 mL, depending on the product).
Which labeler/manufacturers appear for naloxone injection?
Common supply patterns in the US market for naloxone injection:
- Generic injectables are supplied by multiple distributors and labelers; the “manufacturer” on the labeler field may differ from the actual contract manufacturing site.
- Strength and packaging drive which labelers show up under specific NDCs (for example, single-dose vials vs multi-dose packages).
What about naloxone API sourcing?
Naloxone API sourcing typically comes from:
- Chemical manufacturers producing naloxone base and related intermediates.
- API sold into contract manufacturing of drug product by injectable fill-finish sites.
- Separate supply chains for sterile drug product and for API, with different compliance profiles (CGMP, DMF-linked).
Which companies supply naloxone nasal spray?
Featured answer: Naloxone nasal spray supply is tied to the marketed product authorization holder and its contract manufacturing network for sterile spray-drug formulation and delivery device assembly.
What delivery-device partners matter for nasal spray?
Key supplier types for nasal spray include:
- Drug product manufacturer (formulation + assembly of spray components)
- Device component suppliers (sprayer, metering, atomization components)
- Packaging and labeling subcontractors
Which companies supply naloxone autoinjectors?
Featured answer: Naloxone autoinjector supply is linked to the autoinjector platform manufacturer and the drug-product fill-finish/assembly network tied to the specific authorized product.
What manufacturing chain is involved?
Typical autoinjector chain:
- Sterile naloxone solution manufacturing (drug substance already supplied or manufactured separately)
- Fill-finish and assembly into the autoinjector
- Component suppliers for the spring/needle mechanism, cartridge, and outer housing
What patents and exclusivity affect naloxone product supply?
Featured answer: Naloxone is largely off-patent for core composition in most jurisdictions, so supply is dominated by generic drug-product registrations and manufacturing capacity rather than patent-led exclusivity.
Does naloxone have Orange Book exclusivity that blocks generics?
In general market structure:
- Naloxone’s branded status does not typically translate into long exclusivity blocking generic injectable supply.
- Bottle-neck effects are more often CGMP capacity, sterile manufacturing throughput, and device assembly constraints than hard patent barriers.
What FDA status controls which naloxone suppliers can sell?
Featured answer: FDA status is driven by approved NDA/ANDA labeling and current manufacturing compliance, not by ongoing exclusivity.
How to interpret supplier eligibility
- For injectables, the controlling documents are FDA-approved labeling and CGMP compliance for the drug product manufacturing site.
- For device formats (nasal spray, autoinjector), the integration of drug and device performance specifications affects supplier qualification and sustained launch/replenishment.
What generic entry risks exist for naloxone?
Featured answer: Generic entry risks are capacity and quality driven: sterile manufacturing scale-up, device assembly yield, and consistent drug release performance across lots.
Supply continuity constraints
- Sterile filling line availability
- Filter integrity and hold-time controls
- Device assembly automation and component availability (spray nozzle, actuator, cartridge)
How does naloxone supply compare across injectable vs nasal spray vs autoinjector?
Featured answer: Injectable naloxone has the broadest supplier base; device formats concentrate supply among fewer qualified manufacturers because device assembly and performance specs add complexity.
Business impact by format
- Injectable: more interchangeable across suppliers by NDC/label strength, but formulation differences still exist by product.
- Nasal/autoinjector: fewer substitutes in practice because device form factor and performance drive procurement decisions.
Key Takeaways
- Naloxone supply in the US is dominated by generic injectable manufacturers plus a smaller number of qualified suppliers for nasal spray and autoinjectors.
- Supplier identification is NDC-specific and dosage-form-specific; “supplier” can mean labeler, drug-product manufacturer, or device assembly partner.
- For market access, the binding constraints are FDA product approvals, CGMP capability, and device assembly/lot-release performance rather than active patent exclusivity.
FAQs
- Who are the main FDA labelers for naloxone injection in the US?
- Are naloxone nasal spray and autoinjectors interchangeable with naloxone injection for procurement?
- What regulatory filings (ANDA/NDA) govern naloxone generics by dosage form?
- How do device component supply constraints affect naloxone autoinjector availability?
- Do naloxone product suppliers change frequently due to contract manufacturing swaps?
References
- US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- US Food and Drug Administration. Drug Approval Reports and Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/
- US Food and Drug Administration. NDC Directory (NDC lookup via NDC Database). https://www.accessdata.fda.gov/scripts/cder/ndc/
